{"id":"carpipramine","rwe":[{"pmid":"39005934","year":"2024","title":"Structure-based screening of FDA-approved drugs identifies potential histone deacetylase 3 repurposed inhibitor: molecular docking and molecular dynamic simulation approaches.","finding":"","journal":"Frontiers in pharmacology","studyType":"Clinical Study"},{"pmid":"38373093","year":"2025","title":"Unlocking therapeutic potential: computational insights into TREM2 protein targeting with FDA-approved drugs for neurodegeneration.","finding":"","journal":"Journal of biomolecular structure & dynamics","studyType":"Clinical Study"},{"pmid":"25525363","year":"2014","title":"Iminodibenzyl class antipsychotics for schizophrenia: a systematic review and meta-analysis of carpipramine, clocapramine, and mosapramine.","finding":"","journal":"Neuropsychiatric disease and treatment","studyType":"Clinical Study"},{"pmid":"15519367","year":"2004","title":"Atypical properties of several classes of antipsychotic drugs on the basis of differential induction of Fos-like immunoreactivity in the rat brain.","finding":"","journal":"Life sciences","studyType":"Clinical Study"},{"pmid":"14522030","year":"2003","title":"Simultaneous determination of four antipsychotic drugs in plasma by high-performance liquid chromatography. Application to management of acute intoxications.","finding":"","journal":"Journal of chromatography. B, Analytical technologies in the biomedical and life sciences","studyType":"Clinical Study"}],"tags":[{"label":"carpipramine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"D(2) dopamine receptor","category":"target"},{"label":"DRD2","category":"gene"},{"label":"DRD3","category":"gene"},{"label":"Active","category":"status"},{"label":"Anti-Anxiety Agents","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Central Nervous System Depressants","category":"pharmacology"},{"label":"Psychotropic Drugs","category":"pharmacology"},{"label":"Tranquilizing Agents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"defekton","offLabel":[],"synonyms":["carpipramine maleate","carpipramine hydrochloride","defekton","carpipramine dihydrochloride","carpipramine","carbadipimidine","prazinil","carpipramine HCl"],"timeline":[],"brandName":"Defekton","ecosystem":[],"mechanism":{"target":"D(2) dopamine receptor, D(3) dopamine receptor","targets":[{"gene":"DRD2","source":"DrugCentral","target":"D(2) dopamine receptor","protein":"D(2) dopamine receptor"},{"gene":"DRD3","source":"DrugCentral","target":"D(3) dopamine receptor","protein":"D(3) dopamine receptor"}],"modality":"Small Molecule","drugClass":"carpipramine","explanation":"Imagine your brain is like a radio station with many different channels. Dopamine is like a signal that helps different parts of the brain communicate with each other. By blocking dopamine receptors, Defekton can help reduce the volume of this signal, which can help calm down overactive brain activity and alleviate symptoms of certain psychiatric conditions.","oneSentence":"Defekton works by blocking dopamine receptors in the brain, which can help regulate mood and behavior.","technicalDetail":"Defekton exerts its effects by selectively antagonizing the D(2) dopamine receptor subtype, which is involved in the regulation of mood, motivation, and reward processing in the brain."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/517","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CARPIPRAMINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T09:11:10.974117","biosimilars":[],"competitors":[{"drugName":"acepromazine","drugSlug":"acepromazine","fdaApproval":"","relationship":"same-target"},{"drugName":"acetophenazine","drugSlug":"acetophenazine","fdaApproval":"1961-04-05","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"amiodarone","drugSlug":"amiodarone","fdaApproval":"1985-12-24","patentExpiry":"Mar 13, 2029","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"amisulpride","drugSlug":"amisulpride","fdaApproval":"2020-02-26","patentExpiry":"Mar 10, 2031","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"amitriptyline","drugSlug":"amitriptyline","fdaApproval":"1961-04-07","genericCount":33,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"amoxapine","drugSlug":"amoxapine","fdaApproval":"1980-09-22","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"apomorphine","drugSlug":"apomorphine","fdaApproval":"2004-04-20","patentExpiry":"Jun 11, 2030","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"aripiprazole","drugSlug":"aripiprazole","fdaApproval":"2002-11-15","patentExpiry":"Sep 24, 2033","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"aripiprazole lauroxil","drugSlug":"aripiprazole-lauroxil","fdaApproval":"2015-10-05","patentExpiry":"Sep 8, 2035","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"armodafinil","drugSlug":"armodafinil","fdaApproval":"2007-06-05","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-target"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"carpipramine","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"acepromazine","brandName":"acepromazine","genericName":"acepromazine","approvalYear":"","relationship":"same-target"},{"drugId":"acetophenazine","brandName":"acetophenazine","genericName":"acetophenazine","approvalYear":"1961","relationship":"same-target"},{"drugId":"amiodarone","brandName":"amiodarone","genericName":"amiodarone","approvalYear":"1985","relationship":"same-target"},{"drugId":"amisulpride","brandName":"amisulpride","genericName":"amisulpride","approvalYear":"2020","relationship":"same-target"},{"drugId":"amitriptyline","brandName":"amitriptyline","genericName":"amitriptyline","approvalYear":"1961","relationship":"same-target"},{"drugId":"amoxapine","brandName":"amoxapine","genericName":"amoxapine","approvalYear":"1980","relationship":"same-target"},{"drugId":"apomorphine","brandName":"apomorphine","genericName":"apomorphine","approvalYear":"2004","relationship":"same-target"},{"drugId":"aripiprazole","brandName":"aripiprazole","genericName":"aripiprazole","approvalYear":"2002","relationship":"same-target"},{"drugId":"aripiprazole-lauroxil","brandName":"aripiprazole lauroxil","genericName":"aripiprazole lauroxil","approvalYear":"2015","relationship":"same-target"},{"drugId":"armodafinil","brandName":"armodafinil","genericName":"armodafinil","approvalYear":"2007","relationship":"same-target"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"NDDF":"005388","UNII":"8AFK6F91EQ","CHEBI":"CHEBI:31361","INN_ID":"1989","RXNORM":"20342","UMLSCUI":"C0054826","ChEMBL_ID":"CHEMBL2110775","KEGG_DRUG":"D01449","PUBCHEM_CID":"2580","SECONDARY_CAS_RN":"100482-23-3","MESH_SUPPLEMENTAL_RECORD_UI":"C006922"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":55,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[{"date":"2024","pmid":"39005934","title":"Structure-based screening of FDA-approved drugs identifies potential histone deacetylase 3 repurposed inhibitor: molecular docking and molecular dynamic simulation approaches.","journal":"Frontiers in pharmacology"},{"date":"2025 Aug","pmid":"38373093","title":"Unlocking therapeutic potential: computational insights into TREM2 protein targeting with FDA-approved drugs for neurodegeneration.","journal":"Journal of biomolecular structure & dynamics"},{"date":"2014","pmid":"25525363","title":"Iminodibenzyl class antipsychotics for schizophrenia: a systematic review and meta-analysis of carpipramine, clocapramine, and mosapramine.","journal":"Neuropsychiatric disease and treatment"},{"date":"2004 Nov 26","pmid":"15519367","title":"Atypical properties of several classes of antipsychotic drugs on the basis of differential induction of Fos-like immunoreactivity in the rat brain.","journal":"Life sciences"},{"date":"2003 Oct 5","pmid":"14522030","title":"Simultaneous determination of four antipsychotic drugs in plasma by high-performance liquid chromatography. Application to management of acute intoxications.","journal":"Journal of chromatography. B, Analytical technologies in the biomedical and life sciences"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Defekton, also known as carpipramine, is a small molecule drug that targets the D(2) dopamine receptor. It is classified as a carpipramine, but its commercial status and approved indications are unknown. The mechanism of action involves blocking dopamine receptors in the brain, which can help alleviate symptoms of certain psychiatric conditions. However, more information is needed to fully understand its clinical use and safety profile. Further research is required to determine its efficacy and potential side effects.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}